Karyopharm Therapeutics (KPTI) Assets (2012 - 2026)

Karyopharm Therapeutics (KPTI) has reported Assets for 15 consecutive years, with $111.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Assets rose 6.14% year-over-year to $111.3 million; the trailing twelve-month figure through Jun 2026 stood at $111.3 million (up 6.14% YoY), and the FY2025 full-year result was $108.4 million, down 34.06% from the prior year.
• Assets rose to $111.3 million in Q2 2026 per KPTI's latest filing, from $108.4 million in the prior quarter.
• Across five years, Assets topped out at $358.2 million in Q4 2022 and bottomed at $96.2 million in Q3 2025.
• Historically, Assets has averaged $211.5 million across 5 years, with a median of $214.0 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Assets climbed 17.32% in 2022, then plunged 50.99% in 2025.
• Over 5 years, Assets stood at $358.2 million in 2022, then plunged by 32.87% to $240.4 million in 2023, then tumbled by 31.62% to $164.4 million in 2024, then slumped by 34.06% to $108.4 million in 2025, then increased by 2.68% to $111.3 million in 2026.
• According to Business Quant data, Assets over the past three periods registered $111.3 million, $108.4 million, and $96.2 million for Q2 2026, Q4 2025, and Q3 2025 respectively.